医学
麻醉
随机对照试验
安慰剂
可视模拟标度
布比卡因
麻醉药
置信区间
鸦片剂
临床试验
吗啡
类阿片
多中心试验
外科
临床终点
生理盐水
局部麻醉剂
样本量测定
显著性差异
优势比
天花板效应
神经轴阻滞
麻醉剂拮抗剂
作者
Paul Edward Matuszewski,Jacob Jo,Arun Aneja,Abdul Hafeez Diwan,Mark T. Kraus,Eric S. Moghadamian,Raymond D. Wright,Jodi Siegel,Katherine L. Thompson,Eric F. Swart
标识
DOI:10.1097/oi9.0000000000000504
摘要
Objectives: To conduct a pilot randomized control trial evaluating the effectiveness of liposomal bupivacaine to potentially inform a larger trial for effect size and feasibility. Design: Double-Blinded Multicenter Randomized Control Trial. Setting: Level I trauma centers. Patients/Participants: Patients older than 55 years with isolated fragility hip fractures undergoing surgery. Intervention: Liposomal bupivacaine (TX) or placebo injection of saline (P). Main Outcome Measurements: Morphine milliequivalents at 24, 48, and 72 hours postoperatively. Visual analog scale pain scores, Confusion Assessment Method scores, delirium episodes, and surgical/medical complications were all used as secondary outcomes. Results: = 0.37. There was no significant difference in opiate use and visual analog scale scores any time point. There was no difference in Confusion Assessment Method scores or episodes of confusion/delirium nor surgical or medical complications. A 72-hour time point for data collection was not feasible, whereas 48 hours was, with 89% of data points collected. The sample size required for a superiority trial to detect a 20% difference in opioid use would require 518 patients. Conclusions: We were unable to demonstrate a clinical difference between liposomal bupivacaine and placebo in narcotic use, pain scores, or postoperative delirium in geriatric fragility fractures. It is possible that there may be a small effect size that we were unable to detect, and a larger study may demonstrate that. However, given the unlikely large improvement in pain, expense of the medication, and technique dependent nature, a smaller difference does not warrant a larger trial nor uniform administration. Level of Evidence: Level 1. Clinical Trial Registration Number: NCT03289858.
科研通智能强力驱动
Strongly Powered by AbleSci AI